Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Stock Down 7.1 %

Shares of NASDAQ:JAGX opened at $5.00 on Friday. Jaguar Health has a 12-month low of $4.90 and a 12-month high of $540.00. The business has a 50 day moving average of $16.51 and a two-hundred day moving average of $23.23. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.84 and a quick ratio of 1.36.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC purchased a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned approximately 0.22% of Jaguar Health as of its most recent SEC filing. 12.04% of the stock is currently owned by hedge funds and other institutional investors.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.